Literature DB >> 7780127

Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V.

M J Heeb1, Y Kojima, J S Greengard, J H Griffin.   

Abstract

Gln506-factor V (FV) was purified from plasma of an individual homozygous for an Arg506Gln mutation in FV that is associated with activated protein C (APC) resistance. Purified Gln506-FV, as well as Gln506-FVa generated by either thrombin or FXa, conveyed APC resistance to FV-deficient plasma in coagulation assays. Clotting assay studies also suggested that APC resistance does not involve any abnormality in FV-APC-cofactor activity. In purified reaction mixtures, Gln506-FVa in comparison to normal FVa showed reduced susceptibility to APC, because it was inactivated approximately 10-fold slower than normal Arg506-FVa. It was previously reported that inactivation of normal FVa by APC involves an initial cleavage at Arg506 followed by phospholipid-dependent cleavage at Arg306. Immunoblot and amino acid sequence analyses showed that the 102-kD heavy chain of Gln506-FVa was cleaved at Arg306 during inactivation by APC in a phospholipid-dependent reaction. This reduced but measurable susceptibility of Gln506-FVa to APC inactivation may help explain why APC resistance is a mild risk factor for thrombosis because APC can inactivate both normal FVa and variant Gln506-FVa. In summary, this study shows that purified Gln506-FV can account for APC resistance of plasma because Gln506-FVa, whether generated by thrombin or FXa, is relatively resistant to APC.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7780127

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  Prothrombotic phenotype of protein Z deficiency.

Authors:  Z F Yin; Z F Huang; J Cui; R Fiehler; N Lasky; D Ginsburg; G J Broze
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

2.  Postmortem diagnosis of Factor V Leiden from paraffin wax embedded tissue.

Authors:  J S Webb; G R Standen; C M Collins; C P Case
Journal:  Clin Mol Pathol       Date:  1996-06

3.  Autolysis loop restricts the specificity of activated protein C: analysis by FRET and functional assays.

Authors:  Shabir H Qureshi; Chandrashekhara Manithody; Jong-Sup Bae; Likui Yang; Alireza R Rezaie
Journal:  Biophys Chem       Date:  2008-02-25       Impact factor: 2.352

4.  Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C.

Authors:  J Petäjä; J A Fernández; A Gruber; J H Griffin
Journal:  J Clin Invest       Date:  1997-06-01       Impact factor: 14.808

5.  The effect of Arg306-->Ala and Arg506-->Gln substitutions in the inactivation of recombinant human factor Va by activated protein C and protein S.

Authors:  J O Egan; M Kalafatis; K G Mann
Journal:  Protein Sci       Date:  1997-09       Impact factor: 6.725

6.  Prevalence of factor V Leiden in a Canadian blood donor population.

Authors:  D H Lee; P A Henderson; M A Blajchman
Journal:  CMAJ       Date:  1996-08-01       Impact factor: 8.262

7.  Nonenzymatic anticoagulant activity of the mutant serine protease Ser360Ala-activated protein C mediated by factor Va.

Authors:  A J Gale; X Sun; M J Heeb; J H Griffin
Journal:  Protein Sci       Date:  1997-01       Impact factor: 6.725

8.  Functional properties and active-site topographies of factor X Gla- and prothrombin Gla-domain chimeras of activated protein C.

Authors:  Shabir H Qureshi; Likui Yang; Chandrashekhara Manithody; Jong-Sup Bae; Alireza R Rezaie
Journal:  Biochim Biophys Acta       Date:  2008-05-19

9.  Late onset thrombosis in a case of severe protein S deficiency due to compound heterozygosity for PROS1 mutations.

Authors:  M J Heeb; S Gandrille; J A Fernandez; J H Griffin; P F Fedullo
Journal:  J Thromb Haemost       Date:  2008-07-01       Impact factor: 5.824

10.  Coagulation factor V mediates inhibition of tissue factor signaling by activated protein C in mice.

Authors:  Hai Po H Liang; Edward J Kerschen; Sreemanti Basu; Irene Hernandez; Mark Zogg; Shuang Jia; Martin J Hessner; Raffaella Toso; Alireza R Rezaie; José A Fernández; Rodney M Camire; Wolfram Ruf; John H Griffin; Hartmut Weiler
Journal:  Blood       Date:  2015-09-04       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.